Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal propofol dose to suppress etomidate-induced myoclonus in children
ChiCTR2500111596Phase 4Not yet recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of propofol in myoclonus (4 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Frequency and grading of myoclonus at 120 seconds after etomidate or propofol administration. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
propofol
03
Conditions
myoclonus
Beyond the preview
Go deeper on ChiCTR2500111596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111596.